Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Taking Control Of Your Diabetes®. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Taking Control Of Your Diabetes® or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

GLP 1s - One Class of Drugs with Many Different Names

34:43
 
Share
 

Manage episode 476909269 series 3331397
Content provided by Taking Control Of Your Diabetes®. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Taking Control Of Your Diabetes® or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this episode, Dr. Jeremy Pettus and Dr. Steve Edelman go head-to-head in a friendly face-off between two of the most talked-about medications in diabetes and weight management: Ozempic and Mounjaro. Both are part of the powerful GLP-1 class, but which one might be better for you? From A1C reduction and weight loss to heart and kidney protection, ease of use, side effects, and insurance coverage—Drs. E & P walk you through a category-by-category comparison. They bring the clinical data and their own real-world patient experience to help you understand the key differences (and similarities) between these leading therapies. Whether you're managing type 2 diabetes, living with type 1, or exploring options for weight loss, this episode is designed to help you make an informed decision with your healthcare provider.

Key Topics:


    • How These Medications Work: Learn the difference between GLP-1 and dual agonist therapies
    • A1C Reduction: See which drug leads to greater blood sugar improvements based on head-to-head clinical trials.
    • Weight Loss: Discover how much weight patients lose on each medication—and why Mounjaro often shows stronger results.
    • Heart Health: Understand which medication has FDA approval for cardiovascular protection and what’s still under investigation.
    • Kidney Protection: Explore the latest studies showing Ozempic’s ability to slow kidney disease progression.
    • Side Effects: Get practical tips on managing common GI side effects and why titration matters.
    • Ease of Use: Compare how the pens work, dosing flexibility, and what may be easier for patients day to day.
    • Sleep Apnea: Find out how Mounjaro earned a new indication for reducing sleep apnea severity—especially through weight loss.
    • Access for Type 1s: Learn why these meds aren’t yet approved for T1D and how some patients are still getting them.
    • Emerging Indications: Hear about new uses for these meds, including fatty liver, osteoarthritis, and even alcohol reduction.
    • How to Choose: Get expert guidance on which medication may be right for you based on your goals and health needs.

★ Support this podcast ★
  continue reading

73 episodes

Artwork
iconShare
 
Manage episode 476909269 series 3331397
Content provided by Taking Control Of Your Diabetes®. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Taking Control Of Your Diabetes® or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this episode, Dr. Jeremy Pettus and Dr. Steve Edelman go head-to-head in a friendly face-off between two of the most talked-about medications in diabetes and weight management: Ozempic and Mounjaro. Both are part of the powerful GLP-1 class, but which one might be better for you? From A1C reduction and weight loss to heart and kidney protection, ease of use, side effects, and insurance coverage—Drs. E & P walk you through a category-by-category comparison. They bring the clinical data and their own real-world patient experience to help you understand the key differences (and similarities) between these leading therapies. Whether you're managing type 2 diabetes, living with type 1, or exploring options for weight loss, this episode is designed to help you make an informed decision with your healthcare provider.

Key Topics:


    • How These Medications Work: Learn the difference between GLP-1 and dual agonist therapies
    • A1C Reduction: See which drug leads to greater blood sugar improvements based on head-to-head clinical trials.
    • Weight Loss: Discover how much weight patients lose on each medication—and why Mounjaro often shows stronger results.
    • Heart Health: Understand which medication has FDA approval for cardiovascular protection and what’s still under investigation.
    • Kidney Protection: Explore the latest studies showing Ozempic’s ability to slow kidney disease progression.
    • Side Effects: Get practical tips on managing common GI side effects and why titration matters.
    • Ease of Use: Compare how the pens work, dosing flexibility, and what may be easier for patients day to day.
    • Sleep Apnea: Find out how Mounjaro earned a new indication for reducing sleep apnea severity—especially through weight loss.
    • Access for Type 1s: Learn why these meds aren’t yet approved for T1D and how some patients are still getting them.
    • Emerging Indications: Hear about new uses for these meds, including fatty liver, osteoarthritis, and even alcohol reduction.
    • How to Choose: Get expert guidance on which medication may be right for you based on your goals and health needs.

★ Support this podcast ★
  continue reading

73 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play